Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06824064 | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer(VISTA-1) | recruiting | Phase 2 | 150 | Riboscience, LLC.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT07581626 | Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | May 18, 2026 |
| clinicaltrials |
| NCT07591597 | A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer(IGNITE-CRC) | not yet recruiting | Phase 1 / Phase 2 | 68 | National Cancer Center Hospital EastOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06300463 | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | recruiting | Phase 2 | 24 | Weill Medical College of Cornell UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06580574 | Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers | recruiting | Phase 2 | 34 | Peking UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07586813 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors(N01-A-PICIT-GI) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07365592 | Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC(Neo-CD) | recruiting | Phase 1 / Phase 2 | 138 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07585279 | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 408 | Hebei Medical University Fourth HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05672524 | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07446387 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 70 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581912 | Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases(FALCO) | recruiting | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06758830 | Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. | recruiting | Phase 2 / Phase 3 | 400 | National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05694936 | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 38 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07448142 | Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | recruiting | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07570914 | Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | not yet recruiting | Phase 2 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 6, 2026 | clinicaltrials |
| NCT05692024 | COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER(COMMENCER) | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 165 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07503756 | JS212 Combination Therapies in Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05961709 | The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | recruiting | Phase 1 / Phase 2 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562490 | A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer(CLEAR-04) | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562503 | Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer(CLEAR-03) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562659 | Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer(CLEAR-01) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562711 | Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer(CLEAR-02) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05776381 | The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp | not yet recruiting | Phase 2 | 110 | Vejle HospitalOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06356584 | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases | recruiting | Phase 2 | 62 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06589830 | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Suzhou Teligene Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06778382 | Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer. | recruiting | Phase 2 | 22 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06911684 | Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. | recruiting | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07381309 | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM(VVSHIP) | not yet recruiting | Phase 2 | 114 | Jun HuangOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06002789 | Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | recruiting | Phase 2 | 17 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06204094 | Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer(CASINOs) | recruiting | Phase 2 | 37 | Jinhua Central HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07542262 | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers(NIVO402025) | enrolling by invitation | Phase 2 | 128 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07549906 | Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study | not yet recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT06475352 | Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme(FUDOSE) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | not yet recruiting | Phase 2 | 20 | Chongqing University Cancer HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | recruiting | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | recruiting | Phase 2 / Phase 3 | 156 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07405476 | Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment | recruiting | Phase 2 | 38 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 18, 2026source: clinicaltrials